Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LYN_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LYN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LYN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LYN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LYN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:001095210 | Cervix | CC | positive regulation of peptidase activity | 54/2311 | 197/18723 | 8.06e-09 | 6.99e-07 | 54 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
GO:001095010 | Cervix | CC | positive regulation of endopeptidase activity | 48/2311 | 179/18723 | 1.12e-07 | 5.71e-06 | 48 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0512010 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0466618 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa04662 | Oral cavity | OSCC | B cell receptor signaling pathway | 48/3704 | 84/8465 | 9.02e-03 | 2.01e-02 | 1.03e-02 | 48 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa05167113 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
hsa05417113 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa0512017 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0406411 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0466619 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa046621 | Oral cavity | OSCC | B cell receptor signaling pathway | 48/3704 | 84/8465 | 9.02e-03 | 2.01e-02 | 1.03e-02 | 48 |
hsa0516929 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0520324 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 |
hsa0512024 | Oral cavity | LP | Epithelial cell signaling in Helicobacter pylori infection | 38/2418 | 70/8465 | 5.17e-06 | 4.20e-05 | 2.71e-05 | 38 |
hsa05167210 | Oral cavity | LP | Kaposi sarcoma-associated herpesvirus infection | 84/2418 | 194/8465 | 6.66e-06 | 5.16e-05 | 3.33e-05 | 84 |
hsa05417210 | Oral cavity | LP | Lipid and atherosclerosis | 84/2418 | 215/8465 | 5.02e-04 | 2.61e-03 | 1.68e-03 | 84 |
hsa0516936 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0520334 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 |
hsa0512034 | Oral cavity | LP | Epithelial cell signaling in Helicobacter pylori infection | 38/2418 | 70/8465 | 5.17e-06 | 4.20e-05 | 2.71e-05 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LYN | SNV | Missense_Mutation | | c.475N>A | p.Glu159Lys | p.E159K | P07948 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
LYN | SNV | Missense_Mutation | | c.627N>T | p.Lys209Asn | p.K209N | P07948 | protein_coding | tolerated(0.16) | benign(0.056) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
LYN | SNV | Missense_Mutation | | c.57N>C | p.Leu19Phe | p.L19F | P07948 | protein_coding | tolerated(0.72) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | novel | c.1096N>T | p.Arg366Trp | p.R366W | P07948 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | novel | c.1442N>C | p.Lys481Thr | p.K481T | P07948 | protein_coding | deleterious(0.01) | benign(0.432) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LYN | SNV | Missense_Mutation | | c.1508N>A | p.Ala503Asp | p.A503D | P07948 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | | c.1252N>A | p.Gly418Arg | p.G418R | P07948 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A155-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
LYN | SNV | Missense_Mutation | novel | c.905N>C | p.Leu302Pro | p.L302P | P07948 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LYN | SNV | Missense_Mutation | | c.20A>T | p.Lys7Ile | p.K7I | P07948 | protein_coding | deleterious(0.01) | possibly_damaging(0.482) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
LYN | SNV | Missense_Mutation | | c.907G>A | p.Val303Met | p.V303M | P07948 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CYC-116 | CYC-116 | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | ILORASERTIB | ILORASERTIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | SORAFENIB | SORAFENIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 178102666 | | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | GW459057A | GW459057A | 16890436 |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | NINTEDANIB | NINTEDANIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | NILOTINIB | NILOTINIB | 18191450 |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | MASITINIB | MASITINIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Bafetinib | BAFETINIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 178103494 | IBRUTINIB | |